Secarna enters co-development pact with MetP Pharma for transnasally delivered antisense oligonucleotide-based CNS therapeutics
Secarna Pharmaceuticals (Secarna), a new breed of biopharmaceutical company, has entered into a co-development agreement with MetP Pharma (MetP), a privately held... Read More
Case study – Alcon – Novartis Spin-Off: Alcon to become standalone Trading Company
Posted on04 Jul 2018
Comments0
Novartis AG intends to spinoff its ophthalmology division, Alcon, into a separately-traded standalone company. Preset: Novartis acquired Alcon in 2011. The Alcon... Read More
Sanofi and Lonza’s Strategic Partnership to Establish a Large-Scale Biologics Production Facility
Posted on28 Feb 2017
Comments0
Sanofi and Lonza announced today that they have entered into a strategic partnership to build and operate a large-scale mammalian cell culture... Read More
Case Analysis: Mead Johnson-Reckitt Benckiser Mega Deal
Posted on14 Feb 2017
Comments0
British consumer health giant Reckitt Benckiser agreed to buy pediatric nutrition manufacture Mead Johnson Nutrition Company MJN for US$16.6 billion. Reckitt Benckiser,... Read More
Evolent Health to Acquire Valence Health
Evolent Health will acquire the majority of Valence Health’s business for approximately $145 million. The combination of Evolent and Valence Health brings... Read More
Nichi-Iko to acquire Sagent Pharmaceuticals for $736 million
Nichi-Iko Pharmaceutical Co. will acquire Sagent Pharmaceuticals for $736 million, subject to customary regulatory approvals. The acquisition brings together two leading companies... Read More
Hummingbird Bioscience and Sanofi’s collaboration for novel cancer therapeutics
Hummingbird Bioscience, an innovative biotechnology company focused on the discovery and early development of antibody therapeutics, announced a collaboration with Sanofi, a... Read More
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
Posted on25 Sep 2014
Comments0
Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine CV9202 CV9202 is based on CureVac’s... Read More